Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination

Minke, J.M.; Fischer, Laurent; Baudu, P.; Guigal, Pierre-Michel; Sindle, T.; Mumford, J. A.; Audonnet, Jean-Christophe

doi:10.1016/j.vetimm.2006.01.008

Cited by 44 publications

(41 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Poxvirus vectored vaccines, with enhanced safety due to limited replication are of particular interest. Indeed, recombinant canarypox virus based vaccines for the prevention of equine influenza, West Nile virus or equine herpesvirus infections have already been developed for use in horses, and for the prevention of the closely related BTV in sheep [41]–[44]. Vaccination of horses with recombinant MVA based vectors has also been shown to be an effective means of inducing protective immunity to influenza virus infection [32], [45].…”

Section: Discussionmentioning

confidence: 99%

Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)

et al. 2009

View full text Add to dashboard Cite

BackgroundAfrican horse sickness virus (AHSV) causes a non-contagious, infectious disease in equids, with mortality rates that can exceed 90% in susceptible horse populations. AHSV vaccines play a crucial role in the control of the disease; however, there are concerns over the use of polyvalent live attenuated vaccines particularly in areas where AHSV is not endemic. Therefore, it is important to consider alternative approaches for AHSV vaccine development. We have carried out a pilot study to investigate the ability of recombinant modified vaccinia Ankara (MVA) vaccines expressing VP2, VP7 or NS3 genes of AHSV to stimulate immune responses against AHSV antigens in the horse.Methodology/Principal FindingsVP2, VP7 and NS3 genes from AHSV-4/Madrid87 were cloned into the vaccinia transfer vector pSC11 and recombinant MVA viruses generated. Antigen expression or transcription of the AHSV genes from cells infected with the recombinant viruses was confirmed. Pairs of ponies were vaccinated with MVAVP2, MVAVP7 or MVANS3 and both MVA vector and AHSV antigen-specific antibody responses were analysed. Vaccination with MVAVP2 induced a strong AHSV neutralising antibody response (VN titre up to a value of 2). MVAVP7 also induced AHSV antigen–specific responses, detected by western blotting. NS3 specific antibody responses were not detected.ConclusionsThis pilot study demonstrates the immunogenicity of recombinant MVA vectored AHSV vaccines, in particular MVAVP2, and indicates that further work to investigate whether these vaccines would confer protection from lethal AHSV challenge in the horse is justifiable.

show abstract

Section: Discussionmentioning

confidence: 99%

Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)

et al. 2009

View full text Add to dashboard Cite

show abstract

“…The amount of VN antibody was increased in ponies vaccinated with the DNA/DMRIE-DOPE vaccine, and the duration of nasopharyngeal virus excretion after experimental infection with EHV-1 was reduced following immunisation with a DNA vaccine adjuvanted with aluminium phosphate. Cell-associated viraemia was not affected by vaccination [113]. It is clear that DNA vaccination efficiently stimulates an EHV-1 specific antibody response in the horse but so far no cellular immune responses have been studied.…”

Section: Dna Vaccines Against Ehv-1mentioning

confidence: 93%

“…Clinical signs of disease induced by EHV-4 challenge were also reduced in vaccinated ponies [112]. In a recent study, ponies vaccinated twice with a conventional whole EHV-1 inactivated vaccine adjuvanted with carbomer developed a strong humoral response (both CF and VN antibodies) after both immunisations [113]. No mucosal humoral immune response has been directly induced by intramuscular immunisations with an inactivated EHV-1 vaccine [62].…”

Section: Inactivated Whole Ehv-1 Vaccines and Sub-unit Vaccinesmentioning

confidence: 95%

“…Recombinant poxviruses derived from vaccinia or avipoxvirus (i.e. canarypox or fowlpox virus) are commercially available and several recombinant canarypoxbased vaccines have been developed for the horse [65,113].…”

Section: Poxvirus-based Vector Vaccine For Ehv-1mentioning

confidence: 99%

“…A marked reduction of virus excretion in the vaccinates was noted when compared to ponies vaccinated without the carbopol adjuvant or control unvaccinated ponies experimentally infected with EHV-1. However, vaccination did not affect the prevalence and duration of cell-associated viraemia [113,154]. It was speculated that none of the EHV-1 glycoproteins chosen contained CTL epitopes, which could be a potential explanation for the lack of control of cellassociated viraemia.…”

Section: Poxvirus-based Vector Vaccine For Ehv-1mentioning

confidence: 99%

See 2 more Smart Citations

Equine Herpes Virus-1: Virus, Immunity and Vaccines

Paillot¹,

Case²,

Ross³

et al. 2008

TOVSJ

View full text Add to dashboard Cite

Equine Herpes virus-1 (EHV-1) is one of the most common respiratory pathogens of the horse. EHV-1 induces several clinical signs of disease ranging in severity, from mild respiratory distress to abortion in pregnant mares, neonatal foal death and neuropathogenic disorders. This review details some aspects of EHV-1 biology, its life cycle and pathogenicity in the natural host. Protective immunity stimulated by natural EHV-1 infection, which is short lived and depends of both humoral and cellular immune responses, will also be treated here. Vaccination remains today one of the best options to fight EHV-1 infection and several different strategies of vaccination that have been investigated and developed over the past decades will be presented in this report.

show abstract

Recombinant poxvirus vaccines in biomedical research

2007

View full text Add to dashboard Cite

In biomedical research recombinant poxviruses are investigated as important candidate medicines to derive advanced options for prevention and/or treatment of infectious diseases or cancer. Genetically engineered viruses can readily synthesize biologically active heterologous proteins, serve to determine relevant targets of cell-mediated and humoral immunity, and identify types of immune responses needed for protection against a multitude of different specific diseases. Substantial progress in vaccine development is based on the availability of exceptionally safe but efficient carrier viruses, on increasingly versatile vector technologies and on the feasibility of large scale manufacturing. Moreover, advances in deciphering the molecular pathways regulating poxvirus-host interactions will provide additional means to potently activate innate immune stimulation upon vaccination and to derive vectors with specifically targeted replicative capacity for experimental tumor therapy.

show abstract

Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination

Cited by 44 publications

References 17 publications

Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)

Induction of Antibody Responses to African Horse Sickness Virus (AHSV) in Ponies after Vaccination with Recombinant Modified Vaccinia Ankara (MVA)

Equine Herpes Virus-1: Virus, Immunity and Vaccines

Recombinant poxvirus vaccines in biomedical research

Contact Info

Product

Resources

About